Payment overview · 2025
General Payments
$623.46
36 reported records · 15 companies
Healthcare provider profile · identity verified
Roger S. Mcclintock, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TAYLORVILLE, IL · NPI 1043318066
Verified facts
What the public records show
CMS Open Payments records show Roger S. Mcclintock, M.D. received $623.46 in general payments during 2025 across 36 reported records.
Amgen Inc. accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $155.20 | 24.9% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $121.95 | 19.6% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.11 | 9.3% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $44.97 | 7.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.48 | 6.2% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $36.36 | 5.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.75 | 4.0% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $24.57 | 3.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.51 | 3.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.21 | 2.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.78 | 2.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.08 | 2.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.71 | 2.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.14 | 2.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.64 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $591.19 | 35 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $123.27 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.95 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $70.53 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.11 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $56.49 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $44.97 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.84 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $36.36 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.93 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 115 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
115 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
162 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 648 | 187 |
| Lisinopril | Lisinopril | 623 | 177 |
| Gabapentin | Gabapentin | 548 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 534 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 525 | 115 |
| Potassium Chloride | Potassium Chloride | 500 | 111 |
| Furosemide | Furosemide | 412 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 393 | 96 |
| Eliquis | Apixaban | 369 | 54 |
| Omeprazole | Omeprazole | 361 | 115 |
| Sertraline Hcl | Sertraline Hcl | 357 | 82 |
| Montelukast Sodium | Montelukast Sodium | 328 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 317 | 98 |
| Metformin Hcl | Metformin Hcl | 294 | 89 |
| Pravastatin Sodium | Pravastatin Sodium | 293 | 76 |
| Losartan Potassium | Losartan Potassium | 285 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 259 | 70 |
| Trazodone Hcl | Trazodone Hcl | 241 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 220 | 65 |
| Glipizide Er | Glipizide | 213 | 63 |
| Warfarin Sodium | Warfarin Sodium | 191 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 184 | 71 |
| Famotidine | Famotidine | 183 | 56 |
| Diclofenac Sodium | Diclofenac Sodium | 179 | 65 |
| Allopurinol | Allopurinol | 176 | 39 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 169 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 50 |
| Jardiance | Empagliflozin | 162 | 37 |
| Simvastatin | Simvastatin | 159 | 39 |
| Donepezil Hcl | Donepezil Hcl | 150 | 28 |
| Spironolactone | Spironolactone | 149 | 46 |
| Doxazosin Mesylate | Doxazosin Mesylate | 136 | 43 |
| Carvedilol | Carvedilol | 132 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 45 |
| Glipizide | Glipizide | 120 | 33 |
| Tradjenta | Linagliptin | 120 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 119 | 38 |
| Clonidine Hcl | Clonidine Hcl | 118 | 37 |
| Buspirone Hcl | Buspirone Hcl | 115 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 115 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 113 | 52 |
| Azelastine Hcl | Azelastine Hcl | 110 | 53 |
| Ropinirole Hcl | Ropinirole Hcl | 110 | 26 |
| Ozempic | Semaglutide | 108 | 26 |
| Clonidine | Clonidine | 106 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 38 |
| Memantine Hcl | Memantine Hcl | 100 | 14 |
| Nabumetone | Nabumetone | 98 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 16 |
| Azithromycin | Azithromycin | 96 | 76 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 94 | 25 |
| Ezetimibe | Ezetimibe | 91 | 29 |
| Amoxicillin | Amoxicillin | 89 | 69 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 88 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 87 | 68 |
| Cephalexin | Cephalexin | 81 | 56 |
| Fenofibrate | Fenofibrate Nanocrystallized | 80 | 24 |
| Mirtazapine | Mirtazapine | 78 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 74 | 20 |
| Myrbetriq | Mirabegron | 72 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 20 |
| Lactulose | Lactulose | 71 | 28 |
| Bupropion Hcl Sr | Bupropion Hcl | 70 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 70 | 25 |
| Finasteride | Finasteride | 69 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 21 |
| Methylprednisolone | Methylprednisolone | 68 | 62 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 46 |
| Xarelto | Rivaroxaban | 68 | 13 |
| Lovastatin | Lovastatin | 67 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 13 |
| Meloxicam | Meloxicam | 66 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 16 |
| Mupirocin | Mupirocin | 63 | 52 |
| Nystatin | Nystatin | 63 | 29 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 62 | suppressed |
| Vascepa | Icosapent Ethyl | 61 | suppressed |
| Levofloxacin | Levofloxacin | 60 | 50 |
| Prednisone | Prednisone | 60 | 27 |
| Atenolol | Atenolol | 58 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 58 | 19 |
| Meclizine Hcl | Meclizine Hcl | 57 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 33 |
| Torsemide | Torsemide | 57 | 13 |
| Hydrocortisone | Hydrocortisone | 55 | 14 |
| Lidocaine | Lidocaine | 55 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 53 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 51 | suppressed |
| Fenofibrate | Fenofibrate | 50 | 18 |
| Topiramate | Topiramate | 50 | suppressed |
| Digoxin | Digoxin | 48 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | 15 |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 12 |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 23 |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | 16 |
| Sucralfate | Sucralfate | 38 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 36 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Carbamazepine | Carbamazepine | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 24 |
| Risperidone | Risperidone | 35 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 23 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 24 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 30 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 29 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | 12 |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 14 |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | 13 |
| Lithium Carbonate | Lithium Carbonate | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 16 |
| Diclofenac Potassium | Diclofenac Potassium | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Ertapenem | Ertapenem Sodium | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 15 | 14 |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 11 |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Norethindrone | Norethindrone | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | 11 |
| Tobramycin | Tobramycin | 14 | 11 |
| Ursodiol | Ursodiol | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $623.46 · 36 records | Amgen Inc. | BEYFORTUS, BREZTRI, EVENITY, FREESTYLE LIBRE 3, GEMTESA, Korlym, LEQVIO, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, YUPELRI, ZENPEP, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error